Author of

• 25955

  +

  P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27422

    +

    P3.01-66 - Clinicopathological Characteristics and Mutation Status of Pulmonary Invasive Mucinous Adenocarcinoma (ID 12731)

    12:00 - 13:30  |  Presenting Author(s): Fangliang Lu
    • Abstract

    Background
    

    In the 2015 classification, invasive mucinous adenocarcinoma（IMA）is categorized as one but an uncommon subtype of lung adenocarcinoma. This study attempted to clarify the clinicopathological characteristics and mutation status of IMA.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A total of 37 patients with IMA from among 1376 surgically resected patients with lung adenocarcinoma were enrolled. We analyzed them from the standpoints of clinicopathological characteristics, mutation status and the prognosis.

    4c3880bb027f159e801041b1021e88e8 Result
    

    KRAS mutations were observed in 9 patients and all of them were Codon 12 mutations. A total of 10 cases exhibited EGFR mutations. ALK rearrangement was detected in only 1 case. The DFS at 5 years were 68.0%. On univariate analysis for DFS, high CEA level (p =0.024), lymphatic permeation and vascular invasion (p =0.015), pleural invasion (p =0.031), tumor size (p=0.023) and N staging(p=0.027) were poor prognostic predictors for DFS.

    Characteristic	n(%)
    Age(years)
    <65	23(62.2)
    ≥65	14(37.8)
    Sex
    Male	15(40.5)
    Female	22(59.5)
    Smoking
    Positive	13(35.1)
    Negative	24(64.9)
    Tumor size(cm)
    <3	18(48.6)
    ≥3	19(51.4)
    CEA level(ng/ml)
    <5	25(67.6)
    ≥5	12(32.4)
    SUVmax
    <5	9(40.9)
    ≥5	13(59.1)
    Pleural invasion
    Positive	13(35.1)
    Negative	24(64.9)
    Lymphatic permeation and Vascular invasion
    Positive	4(10.8)
    Negative	33(89.2)
    N stage
    N0	24(64.9)
    N1 and N2	13(35.1)

    Mutation	n(%)
    EGFR
    Exon 18	1(3.0)
    Exon 19	4(12.1)
    Exon 20 and 21	1(3.0)
    Exon 21	4(12.1)
    None	23(69.7)
    KRAS
    Codon 12	9(29.0)
    Codon 13	0
    None	22(71.0)
    EGFR, epithelial growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The results revealed that different mutation statuses were observed in IMA. So, we believe that IMA would be subclassified into distinct subtypes with mutation status. And CEA level, lymphatic permeation and vascular invasion, pleural invasion, tumor size and N staging may be the factors related to mitigating DFS in IMA.

    6f8b794f3246b0c1e1780bb4d4d5dc53